{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:22:35Z","timestamp":1761513755900},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High replicative fitness is a general determinant of a multidrug resistance phenotype and may explain lower sensitivity to direct-acting antiviral agents (DAAs) in some hepatitis C virus genotypes. Genetic diversity in the molecular target site of peptidomimetic NS3 protease inhibitors could impact variant replicative fitness and potentially add to virologic treatment failure. We selected NS3 helicase residues near the protease natural substrate in the NS3 domain interface and identified natural variants from a public database. Sequence diversity among different genotypes was identified and subsequently analyzed for potential effects of helicase variants on protein structure and function and phenotypic effects on RNA replication and DAA resistance. We found increased replicative fitness in particular for amino acid substitutions at the NS3 helicase C-terminal helix \u03b1<jats:sub>18<\/jats:sub>. A network of strongly coupled residue pairs is identified. Helix \u03b1<jats:sub>18<\/jats:sub> is part of this regulatory network and connects several NS3 functional elements involved in RNA replication. Among all genotypes we found distinct sequence diversity at helix \u03b1<jats:sub>18<\/jats:sub> in particular for the most difficult-to-treat genotype 3. Our data suggest sequence diversity with implications for virus replicative fitness due to natural variants in helicase helix \u03b1<jats:sub>18<\/jats:sub>.<\/jats:p>","DOI":"10.1038\/srep19526","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T13:19:28Z","timestamp":1453295968000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix \u03b118"],"prefix":"10.1038","volume":"6","author":[{"given":"Claudia","family":"Stross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Shimakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Haselow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monazza Q.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Welsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"key":"BFsrep19526_CR1","doi-asserted-by":"publisher","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","volume":"61","author":"C Welsch","year":"2012","unstructured":"Welsch, C., Jesudian, A., Zeuzem, S. & Jacobson, I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 61, i36\u2013i46 (2012).","journal-title":"Gut."},{"key":"BFsrep19526_CR2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nchembio.1081","volume":"8","author":"SM Saalau-Bethell","year":"2012","unstructured":"Saalau-Bethell, S. M. et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol. 8, 920\u2013925 (2012).","journal-title":"Nat Chem Biol."},{"key":"BFsrep19526_CR3","doi-asserted-by":"publisher","first-page":"14545","DOI":"10.1073\/pnas.0807298105","volume":"105","author":"V Brass","year":"2008","unstructured":"Brass, V. et al. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci USA 105, 14545\u201314550 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep19526_CR4","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1128\/JVI.03188-14","volume":"89","author":"DR McGivern","year":"2015","unstructured":"McGivern, D. R. et al. Protease Inhibitors Block Multiple Functions of the NS3\/4A Protease-Helicase during the Hepatitis C Virus Life Cycle. J Virol. 89, 5362\u20135370 (2015).","journal-title":"J Virol."},{"key":"BFsrep19526_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nature04193","volume":"437","author":"E Meylan","year":"2005","unstructured":"Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 437, 1167\u20131172 (2005).","journal-title":"Nature."},{"key":"BFsrep19526_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jhep.2014.11.009","volume":"62","author":"C Welsch","year":"2015","unstructured":"Welsch, C. et al. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-\u03b2 induction by efficient MAVS cleavage. J Hepatol. 62, 779\u2013784 (2015).","journal-title":"J Hepatol."},{"key":"BFsrep19526_CR7","doi-asserted-by":"publisher","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","volume":"2","author":"L Rong","year":"2010","unstructured":"Rong, L., Dahari, H., Ribeiro, R. M. & Perelson, A. S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2, 30ra32 (2010).","journal-title":"Sci Transl Med."},{"key":"BFsrep19526_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ddtec.2013.12.003","volume":"11","author":"C Welsch","year":"2014","unstructured":"Welsch, C. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. Drug Discov Today Technol. 11, 19\u201325 (2014).","journal-title":"Drug Discov Today Technol."},{"key":"BFsrep19526_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1053\/j.gastro.2011.11.035","volume":"142","author":"C Welsch","year":"2012","unstructured":"Welsch, C. et al. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3\/4A serine protease. Gastroenterology. 142, 654\u2013663 (2012).","journal-title":"Gastroenterology."},{"key":"BFsrep19526_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3851\/IMP2734","volume":"19","author":"G Grammatikos","year":"2014","unstructured":"Grammatikos, G. et al. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients. Antivir Ther. 19, 455\u2013461 (2014).","journal-title":"Antivir Ther."},{"key":"BFsrep19526_CR11","doi-asserted-by":"publisher","first-page":"12098","DOI":"10.1128\/JVI.01860-14","volume":"88","author":"J Sheldon","year":"2014","unstructured":"Sheldon, J. et al. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol. 88, 12098\u201312111 (2014).","journal-title":"J Virol."},{"key":"BFsrep19526_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","volume":"12","author":"P Ferenci","year":"2015","unstructured":"Ferenci, P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 12, 284\u2013292 (2015).","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"BFsrep19526_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","volume":"51","author":"PY Bochud","year":"2009","unstructured":"Bochud, P. Y. et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 51, 655\u2013666 (2009).","journal-title":"J Hepatol."},{"key":"BFsrep19526_CR14","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.1021\/bi00089a032","volume":"32","author":"SM Green","year":"1993","unstructured":"Green, S. M. & Shortle, D. Patterns of nonadditivity between pairs of stability mutations in staphylococcal nuclease. Biochemistry. 32, 10131\u201310139 (1993).","journal-title":"Biochemistry."},{"key":"BFsrep19526_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1006\/jmbi.1993.1412","volume":"232","author":"R Loewenthal","year":"1993","unstructured":"Loewenthal, R., Sancho, J., Reinikainen, T. & Fersht, A. R. Long-range surface charge-charge interactions in proteins. Comparison of experimental results with calculations from a theoretical method. J Mol Biol. 232, 574\u2013583 (1993).","journal-title":"J Mol Biol."},{"key":"BFsrep19526_CR16","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1128\/JVI.03540-13","volume":"88","author":"M Yi","year":"2014","unstructured":"Yi, M. et al. Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol. 88, 3678\u20133694 (2014).","journal-title":"J Virol."},{"key":"BFsrep19526_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/(SICI)1099-1654(199707)7:2<87::AID-RMV188>3.0.CO;2-0","volume":"7","author":"E Domingo","year":"1997","unstructured":"Domingo, E., Men\u00e9ndez-Arias, L. & Holland, J. J. RNA virus fitness. Rev Med Virol. 7, 87\u201396 (1997).","journal-title":"Rev Med Virol."},{"key":"BFsrep19526_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","volume":"140","author":"T Shimakami","year":"2011","unstructured":"Shimakami, T. et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology. 140, 667\u2013675 (2011).","journal-title":"Gastroenterology."},{"key":"BFsrep19526_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.antiviral.2008.11.002","volume":"81","author":"X Qi","year":"2009","unstructured":"Qi, X. et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 81, 166\u2013173 (2009).","journal-title":"Antiviral Res."},{"key":"BFsrep19526_CR20","doi-asserted-by":"publisher","first-page":"34913","DOI":"10.1074\/jbc.M707165200","volume":"282","author":"RK Beran","year":"2007","unstructured":"Beran, R. K., Serebrov, V. & Pyle, A. M. The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J Biol Chem. 282, 34913\u201334920 (2007).","journal-title":"J Biol Chem."},{"key":"BFsrep19526_CR21","doi-asserted-by":"publisher","first-page":"29929","DOI":"10.1074\/jbc.M804065200","volume":"283","author":"RK Beran","year":"2008","unstructured":"Beran, R. K. & Pyle, A. M. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem. 283, 29929\u201329937 (2008).","journal-title":"J Biol Chem."},{"key":"BFsrep19526_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/prot.10180","volume":"48","author":"I Kass","year":"2002","unstructured":"Kass, I. & Horovitz, A. Mapping pathways of allosteric communication in GroEL by analysis of correlated mutations. Proteins. 48, 611\u2013617 (2002).","journal-title":"Proteins."},{"key":"BFsrep19526_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/hep.26671","volume":"59","author":"K Morikawa","year":"2014","unstructured":"Morikawa, K. et al. Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. Hepatology. 59, 423\u2013433 (2014).","journal-title":"Hepatology."},{"key":"BFsrep19526_CR24","doi-asserted-by":"publisher","first-page":"D363","DOI":"10.1093\/nar\/gkl970","volume":"35","author":"C Combet","year":"2007","unstructured":"Combet, C. et al. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res. 35, D363\u2013D366 (2007).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep19526_CR25","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/nar\/gkh340","volume":"32","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792\u20131797 (2004).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep19526_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/molbev\/msp259","volume":"27","author":"M Gouy","year":"2010","unstructured":"Gouy, M., Guindon, S. & Gascuel, O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Molecular Biology and Evolution. 27, 221\u2013224 (2010).","journal-title":"Molecular Biology and Evolution."},{"key":"BFsrep19526_CR27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: A sequence logo generator. Genome Res. 14, 1188\u20131190 (2004).","journal-title":"Genome Res."},{"key":"BFsrep19526_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2144\/000113370","volume":"48","author":"W Deng","year":"2010","unstructured":"Deng, W. et al. DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity and informative sites. BioTechniques. 48, 405\u2013408 (2010).","journal-title":"BioTechniques."},{"key":"BFsrep19526_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0969-2126(00)80025-8","volume":"7","author":"N Yao","year":"1999","unstructured":"Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W. & Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure. 7, 1353\u20131363 (1999).","journal-title":"Structure."},{"key":"BFsrep19526_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep19526_CR31","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/hep.23192","volume":"50","author":"S Susser","year":"2009","unstructured":"Susser, S. et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 50, 1709\u20131718 (2009).","journal-title":"Hepatology."},{"key":"BFsrep19526_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbrc.2012.08.015","volume":"425","author":"I Schechter","year":"2012","unstructured":"Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. 1967. Biochem Biophys Res Commun. 425, 497\u2013502 (2012).","journal-title":"Biochem Biophys Res Commun."},{"key":"BFsrep19526_CR33","doi-asserted-by":"publisher","first-page":"22725","DOI":"10.1074\/jbc.R110.125294","volume":"285","author":"KD Raney","year":"2010","unstructured":"Raney, K. D., Sharma, S. D., Moustafa, I. M. & Cameron, C. E. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem. 285, 22725\u201322731 (2010).","journal-title":"J Biol Chem."},{"key":"BFsrep19526_CR34","first-page":"1","volume":"9","author":"DN Frick","year":"2007","unstructured":"Frick, D. N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol. 9, 1\u201320 (2007).","journal-title":"Curr Issues Mol Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep19526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep19526","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep19526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:39:08Z","timestamp":1672900748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep19526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,10]]}},"alternative-id":["BFsrep19526"],"URL":"https:\/\/doi.org\/10.1038\/srep19526","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,20]]},"assertion":[{"value":"24 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19526"}}